MedTrace Logo

Multi-center Study to Transplant Hepatitis-C Infected Kidneys

NCT03781726 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-01-26

Study results available
· View outcomes & findings →

Summary

Open label multi center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.

Conditions

  • Renal Failure Chronic
  • Hepatitis C

Interventions

DRUG

glecaprevir/pibrentasvir treatment

combination treatment with glecaprevir and pibrentasvir fixed dose tablet.

Sponsors & Collaborators

Principal Investigators

  • Raymond T Chung, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-10
Primary Completion
2020-03-20
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03781726 on ClinicalTrials.gov